Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
CNS companies join forces
June 19, 2006
| A version of this story appeared in
Volume 84, Issue 25
Axonyx and TorreyPines Therapeutics will merge to create a biopharmaceutical company focused on drugs for central nervous system disorders. The new company will keep the TorreyPines Therapeutics name and have its headquarters in San Diego. The combined pipeline boasts eight products in development: two to treat chronic pain and six to treat Alzheimer's disease. The companies plan to seek a partner for the most advanced candidate, Axonyx's Phenserine, now in Phase III trials for Alzheimer's disease.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X